Cecilia Linde

Cecilia Linde's AcademicInfluence.com Rankings

Cecilia Linde

Biology

#11603

World Rank

#15007

Historical Rank

Cell Biology

#594

World Rank

#607

Historical Rank

Immunology

#754

World Rank

#776

Historical Rank

Genetics

#1256

World Rank

#1358

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Cecilia Linde Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Cecilia Linde's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

[2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure]. (2016) (7627)
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (2016) (6692)
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. (2005) (5789)
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. (2016) (5626)
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). (2013) (2221)
Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. (2001) (2186)
Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. (2008) (1099)
Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. (2002) (998)
2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). (2013) (721)
Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association. (2007) (698)
Guidelines for cardiac pacing and cardiac resynchronization therapy. The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association. (2007) (669)
Cardiac resynchronization therapy: Part 1--issues before device implantation. (2005) (505)
Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. (2002) (497)
213 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy (2013) (484)
An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure (2013) (407)
Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. (2003) (348)
2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. (2012) (335)
2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. (2012) (322)
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD (2020) (310)
Effect of QRS Duration and Morphology on Cardiac Resynchronization Therapy Outcomes in Mild Heart Failure: Results From the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) Study (2012) (277)
Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. PIC Study Group. (1997) (259)
Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. (2009) (254)
Results of atrioventricular synchronous pacing with optimized delay in patients with severe congestive heart failure. (1995) (250)
The European cardiac resynchronization therapy survey. (2009) (237)
[Guidelines for the Diagnosis and Treatment of Chronic Heart Failure: executive summary (update 2005)]. (2005) (214)
Cardiac resynchronization therapy: Part 2--issues during and after device implantation and unresolved questions. (2005) (210)
Cardiac Resynchronization Induces Major Structural and Functional Reverse Remodeling in Patients With New York Heart Association Class I/II Heart Failure (2009) (200)
[Guidelines for cardiac pacing and cardiac resynchronization therapy]. (2008) (199)
Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. PIC Study Group. Pacing In Cardiomyopathy. (1999) (174)
Continuous ambulatory right heart pressure measurements with an implantable hemodynamic monitor: a multicenter, 12-month follow-up study of patients with chronic heart failure. (2002) (168)
Sites of left and right ventricular lead implantation and response to cardiac resynchronization therapy observations from the REVERSE trial. (2012) (163)
[Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005)]. (2005) (159)
Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society (2018) (157)
Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. (2013) (149)
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. (2014) (147)
Long-term improvements in quality of life by biventricular pacing in patients with chronic heart failure: results from the Multisite Stimulation in Cardiomyopathy study (MUSTIC). (2003) (132)
2010 Focused Update of ESC Guidelines on device therapy in heart failure (2010) (128)
Association between cardiovascular vs. non‐cardiovascular co‐morbidities and outcomes in heart failure with preserved ejection fraction (2014) (122)
Prevalence, correlates, and prognostic significance of QRS prolongation in heart failure with reduced and preserved ejection fraction. (2013) (120)
The impact of cardiac resynchronization therapy on the incidence of ventricular arrhythmias in mild heart failure. (2011) (107)
The European CRT Survey: 1 year (9–15 months) follow‐up results (2012) (105)
Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection Fraction: A Holistic Proteomic Approach (2017) (102)
Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failure--the REsynchronization reVErses Remodeling in Systolic left vEntricular (2006) (96)
The European Cardiac Resynchronization Therapy Survey: comparison of outcomes between de novo cardiac resynchronization therapy implantations and upgrades (2011) (95)
Cardiac resynchronization therapy (CRT): clinical trials, guidelines, and target populations. (2012) (91)
Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Systolic Heart Failure: The DEFEAT-HF Study. (2016) (91)
CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients—who is doing what to whom and how? (2018) (90)
Current use of implantable electrical devices in Sweden: data from the Swedish pacemaker and implantable cardioverter-defibrillator registry. (2015) (88)
Sequential Biventricular Pacing: (2004) (87)
Reduction of hospital days by biventricular pacing (2000) (84)
Significant improvement of quality of life following atrioventricular synchronous pacing in patients with hypertrophic obstructive cardiomyopathy. Data from 1 year of follow-up. PIC study group. Pacing In Cardiomyopathy. (1999) (82)
The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: results of the REVERSE study. (2015) (82)
Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population. (2009) (80)
Continous haemodynamic monitoring during withdrawal of diuretics in patients with congestive heart failure (2002) (78)
Indications for Cardiac Resynchronization Therapy: A Comparison of the Major International Guidelines. (2018) (77)
European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. (2016) (76)
Women have better long-term prognosis than men after cardiac resynchronization therapy. (2012) (73)
Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care (2020) (72)
New echocardiographic predictors of clinical outcome in patients presenting with heart failure and a preserved left ventricular ejection fraction: a subanalysis of the Ka (Karolinska) Ren (Rennes) Study (2015) (71)
Association between demographic, organizational, clinical, and socio‐economic characteristics and underutilization of cardiac resynchronization therapy: results from the Swedish Heart Failure Registry (2017) (69)
New devices in heart failure: an European Heart Rhythm Association report: developed by the European Heart Rhythm Association; endorsed by the Heart Failure Association. (2014) (68)
The interaction of sex, height, and QRS duration on the effects of cardiac resynchronization therapy on morbidity and mortality: an individual‐patient data meta‐analysis (2018) (64)
Re-used pacemakers--as safe as new? A retrospective case-control study. (1998) (61)
Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning (2020) (61)
Influence of right ventricular pacing site on left ventricular outflow tract obstruction in patients with hypertrophic obstructive cardiomyopathy. (1996) (60)
Monitoring of physical activity and heart rate variability in patients with chronic heart failure using cardiac resynchronization devices. (2005) (60)
Clinical progress after randomized on/off pacemaker treatment for hypertrophic obstructive cardiomyopathy. Pacing in Cardiomyopathy (PIC) Study Group. (1999) (59)
The World Survey of Cardiac Pacing and Implantable Cardioverter Defibrillators: Calendar Year 1997 ‐ Europe (2001) (58)
Temporal characteristics of cardiac memory in humans: vectorcardiographic quantification in a model of cardiac pacing. (2005) (57)
Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review. (2015) (56)
Spatial detection of fetal marker genes expressed at low level in adult human heart tissue (2017) (56)
Association Between Use of Primary Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients with Heart Failure: A Prospective Propensity-Score Matched Analysis from the Swedish Heart Failure Registry. (2019) (55)
Value of exercise echocardiography in heart failure with preserved ejection fraction: a substudy from the KaRen study. (2015) (54)
Rationale and design of the Karolinska‐Rennes (KaRen) prospective study of dyssynchrony in heart failure with preserved ejection fraction (2009) (54)
Implantable Defibrillators Improve Survival in Patients With Mildly Symptomatic Heart Failure Receiving Cardiac Resynchronization Therapy: Analysis of the Long-Term Follow-Up of Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) (2013) (53)
Cardiac resynchronization therapy in asymptomatic or mildly symptomatic heart failure patients in relation to etiology: results from the REVERSE (REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction) study. (2010) (52)
Gender, underutilization of cardiac resynchronization therapy, and prognostic impact of QRS prolongation and left bundle branch block in heart failure. (2015) (50)
The limit of plausibility for predictors of response: application to biventricular pacing. (2012) (48)
Age, prognostic impact of QRS prolongation and left bundle branch block, and utilization of cardiac resynchronization therapy: findings from 14 713 patients in the Swedish Heart Failure Registry (2014) (48)
Effects of cardiac resynchronization therapy on disease progression in chronic heart failure. (2006) (47)
Imaging predictors of response to cardiac resynchronization therapy: left ventricular work asymmetry by echocardiography and septal viability by cardiac magnetic resonance (2020) (47)
Heart failure with a preserved ejection fraction additive value of an exercise stress echocardiography. (2012) (47)
Core curriculum for the heart rhythm specialist. (2009) (47)
Baseline and postoperative levels of C-reactive protein and interleukins as inflammatory predictors of atrial fibrillation following cardiac surgery: a systematic review and meta-analysis. (2017) (46)
Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK (2019) (46)
Opportunity to increase life span in narrow QRS cardiac resynchronization therapy recipients by deactivating ventricular pacing: evidence from randomized controlled trials. (2015) (46)
How to Evaluate Quality‐of‐Life in Pacemaker Patients: Problems and Pitfalls (1996) (44)
Chronic kidney disease and cardiac remodelling in patients with mild heart failure: results from the REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE) study (2012) (44)
Continuous haemodynamic monitoring during withdrawal of diuretics in patients with congestive heart failure. (2002) (44)
Long-term effects of dual chamber pacing in patients with hypertrophic cardiomyopathy without outflow tract obstruction at rest. (1997) (43)
Meta‐analysis of symptomatic response attributable to the pacing component of cardiac resynchronization therapy (2013) (43)
Baseline characteristics of patients with heart failure and preserved ejection fraction included in the Karolinska Rennes (KaRen) study. (2014) (42)
Effects of biventricular pacing on myocardial blood flow and oxygen consumption using carbon-11 acetate positron emission tomography in patients with heart failure. (2003) (41)
Predisposing factors and consequences of elevated biomarker levels in long-distance runners aged >or=55 years. (2009) (41)
Prediction of New-Onset and Recurrent Atrial Fibrillation by Complete Blood Count Tests: A Comprehensive Systematic Review with Meta-Analysis (2017) (41)
Haematological indices as predictors of atrial fibrillation following isolated coronary artery bypass grafting, valvular surgery, or combined procedures: a systematic review with meta-analysis. (2018) (41)
REsynchronization reVErses Remodeling in Systolic left ventricular dysfunction (REVERSE) (2008) (37)
HFpEF and HFrEF exhibit different phenotypes as assessed by leptin and adiponectin. (2017) (36)
Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction). (2011) (36)
Guidelines for the diagnosis and treatment of Chronic Heart Failure : full (2005) (36)
ST2 in heart failure with preserved and reduced ejection fraction (2019) (36)
Dynamic changes in right ventricular pressures during haemodialysis recorded with an implantable haemodynamic monitor. (2006) (35)
Trials of implantable monitoring devices in heart failure: which design is optimal? (2014) (35)
The burden of proof: The current state of atrial fibrillation prevention and treatment trials. (2017) (34)
Correlation between serial measurements of N‐terminal pro brain natriuretic peptide and ambulatory cardiac filling pressures in outpatients with chronic heart failure (2003) (32)
Reflections on EchoCRT: sound guidance on QRS duration and morphology for CRT? (2015) (32)
Upgrades from a previous device compared to de novo cardiac resynchronization therapy in the European Society of Cardiology CRT Survey II (2018) (32)
The effect of duration of follow-up and presence of competing risk on lifespan-gain from implantable cardioverter defibrillator therapy: who benefits the most? (2015) (32)
Impact of Ejection Fraction on the Clinical Response to Cardiac Resynchronization Therapy in Mild Heart Failure (2013) (32)
Left Ventricular Architecture, Long-Term Reverse Remodeling, and Clinical Outcome in Mild Heart Failure With Cardiac Resynchronization: Results From the REVERSE Trial. (2017) (31)
Successful treatment of heart failure with devices requires collaboration (2008) (30)
Cardiac resynchronisation therapy optimisation strategies: systematic classification, detailed analysis, minimum standards and a roadmap for development and testing. (2013) (30)
Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink (2018) (30)
Cardiac resynchronization therapy in chronic heart failure with moderately reduced left ventricular ejection fraction: Lessons from the Multicenter InSync Randomized Clinical Evaluation MIRACLE EF study. (2016) (30)
The European cardiac resynchronization therapy survey: patient selection and implantation practice vary according to centre volume. (2011) (30)
Patient reported outcome in HFpEF: Sex-specific differences in quality of life and association with outcome. (2018) (30)
Real‐World Associations of Renin–Angiotensin–Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New‐Onset Chronic Kidney Disease or Heart Failure in the United Kingdom (2019) (29)
HFpEF and HFrEF Display Different Phenotypes as Assessed by IGF-1 and IGFBP-1. (2017) (28)
Baseline characteristics of patients randomized in The Resynchronization Reverses Remodeling In Systolic Left Ventricular Dysfunction (REVERSE) study. (2008) (28)
Transcriptomics of cardiac biopsies reveals differences in patients with or without diagnostic parameters for heart failure with preserved ejection fraction (2019) (27)
Predictors of short‐term clinical response to cardiac resynchronization therapy (2017) (27)
Features and Predictors of Ascending Aortic Dilatation in Association With a Congenital Bicuspid Aortic Valve (2003) (26)
Pacing for hypertrophic obstructive cardiomyopathy: an update and future directions (2018) (25)
Rapid return of left ventricular outflow tract obstruction and symptoms following cessation of long-term atrioventricular synchronous pacing for obstructive hypertrophic cardiomyopathy. (1999) (25)
New York Heart Association functional class, QRS duration, and survival in heart failure with reduced ejection fraction: implications for cardiac resychronization therapy (2017) (25)
Redefining the Classifications of Response to Cardiac Resynchronization Therapy: Results From the REVERSE Study. (2021) (24)
Optimization of Cardiac Resynchronization Therapy by Continuous Hemodynamic Monitoring: (2004) (24)
Six years follow‐up of an implanted SvO2 sensor in the right ventricle (2004) (23)
Effects of Cardiac Resynchronization Therapy on Cardiac Remodeling and Contractile Function: Results From Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) (2015) (23)
Metabolomic profile in HFpEF vs HFrEF patients. (2020) (23)
History of electrical therapy for the heart (2007) (23)
Changes in right ventricular pressures between hemodialysis sessions recorded by an implantable hemodynamic monitor. (2009) (22)
Current challenges for clinical trials of cardiovascular medical devices. (2014) (22)
European cardiac resynchronization therapy survey II: rationale and design. (2015) (21)
Cardiac Resynchronization Therapy in Patients With New York Heart Association Class I and II Heart Failure: An Approach to 2010 (2010) (21)
Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction (2015) (21)
The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease (2019) (21)
Core curriculum for the heart rhythm specialist: executive summary. (2009) (20)
Ambulatory hemodynamic monitoring from an implanted device: components of continuous 24-hour pressures that correlate to supine resting conditions and acute right heart catheterization. (2006) (20)
Left atrial rather than left ventricular impaired mechanics are associated with the pro‐fibrotic ST2 marker and outcomes in heart failure with preserved ejection fraction (2018) (20)
Myeloperoxidase and related biomarkers are suggestive footprints of endothelial microvascular inflammation in HFpEF patients (2020) (19)
Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes. (2015) (19)
Copeptin in patients with heart failure and preserved ejection fraction: a report from the prospective KaRen-study (2015) (18)
Atrial Rate Adaptive Pacing: What Happens to AV Conduction? (1994) (17)
Comparison of Prognostic Usefulness of Serum Insulin-Like Growth Factor-Binding Protein 7 in Patients With Heart Failure and Preserved Versus Reduced Left Ventricular Ejection Fraction. (2018) (17)
The transition from hypertension to hypertensive heart disease and heart failure: the PREFERS Hypertension study (2020) (17)
Three Year Outcome of Cardiac Resynchronization Therapy: A Single Center Evaluation (2005) (17)
Women and Arrhythmias (2000) (17)
Continuous central haemodynamic measurements during the six‐minute walk test and daily life in patients with chronic heart failure (2009) (16)
Rationale and design of the PREFERS (Preserved and Reduced Ejection Fraction Epidemiological Regional Study) Stockholm heart failure study: an epidemiological regional study in Stockholm county of 2.1 million inhabitants (2016) (16)
Atrial vs. dual-chamber cardiac pacing in sinus node disease: a register-based cohort study. (2008) (16)
Transient repolarization instability following the initiation of cardiac resynchronization therapy. (2011) (15)
Acute haemodynamic effects of increase in paced heart rate in heart failure patients recorded with an implantable haemodynamic monitor. (2011) (15)
Cardiac resynchronization therapy: a breakthrough in heart failure management (2012) (14)
Cardiac output response to changes of the atrioventricular delay in different body positions and during exercise in patients receiving cardiac resynchronization therapy. (2009) (14)
Neural modulation for hypertension and heart failure. (2016) (14)
Precision Medicine for Cardiac Resynchronization: Predicting Quality of Life Benefits for Individual Patients—An Analysis From 5 Clinical Trials (2017) (13)
Cardiac resynchronization therapy: clinical results and evolution of candidate selection (2007) (13)
Continuous Hemodynamic Monitoring in Heart Failure (2002) (13)
A plea for the wider use of CRT-P in candidates for cardiac resynchronisation therapy (2012) (12)
Modification of atrioventricular conduction as adjunct therapy for pacemaker-treated patients with hypertrophic obstructive cardiomyopathy. (1998) (12)
Cardiac resynchronization therapy pacemaker or cardiac resynchronization therapy defibrillator: what determines the choice?-findings from the ESC CRT Survey II. (2019) (12)
Prognostic impact of Framingham heart failure criteria in heart failure with preserved ejection fraction (2019) (11)
[European practice guidelines on cardiac pacemakers and cardiac resynchronization therapy. Working Group of the European Society of Cardiology (ESC) on cardiac pacemakers and cardiac resynchronization therapy. Developed in collaboration with the European Heart Rhythm Association]. (2007) (10)
Is cardiac resynchronization therapy an option in heart failure patients with preserved ejection fraction? Justification for the ongoing KaRen project. (2010) (10)
Risk stratification with echocardiographic biomarkers in heart failure with preserved ejection fraction: the media echo score (2021) (10)
Estimation of cardiac output in patients with congestive heart failure by analysis of right ventricular pressure waveforms (2011) (10)
Cost effectiveness of implementing ESC guidelines for treatment of iron deficiency in heart failure in the Nordic countries (2018) (9)
European Society of Cardiology Quality Indicators for the care and outcomes of cardiac pacing: developed by the Working Group for Cardiac Pacing Quality Indicators in collaboration with the European Heart Rhythm Association of the European Society of Cardiology (2021) (9)
Sex-Related Procedural Aspects and Complications in CRT Survey II: A Multicenter European Experience in 11,088 Patients. (2019) (9)
Importance of structural heart disease and diastolic dysfunction in heart failure with preserved ejection fraction assessed according to the ESC guidelines - A substudy in the Ka (Karolinska) Ren (Rennes) study. (2019) (9)
Quality‐of‐Life in Pacemaker and Implantable Cardioverter Defibrillator Recipients (2000) (9)
Myocardial micro-biopsy procedure for molecular characterization with increased precision and reduced trauma (2020) (9)
Future research prioritization in cardiac resynchronization therapy. (2020) (8)
The Importance of Early Evaluation after Cardiac Resynchronization Therapy to Redefine Response: Pooled Individual Patient Analysis from Five Prospective Studies. (2021) (8)
Reverse mechanical remodeling by biventricular pacing in congestive heart failure: one-year results from patients in atrial fibrillation in the MUSTIC (MUltisite STimulation in Cardiomyopathy) study (2002) (8)
Identifying patients for advanced heart failure therapy by screening patients with cardiac resynchronization therapy or implantable cardioverter-defibrillator: a pilot study. (2013) (8)
Increased iron absorption in patients with chronic heart failure and iron deficiency: Iron absorption in heart failure. (2020) (8)
N-terminal pro-B-type natriuretic peptide in chronic heart failure: The impact of sex across the ejection fraction spectrum. (2019) (8)
Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real‐world data from the Swedish Heart Failure Registry (2020) (8)
Cardiac resynchronization therapy in mild heart failure. (2009) (7)
Circulating neuregulin1‐β in heart failure with preserved and reduced left ventricular ejection fraction (2020) (7)
Cardiac Resynchronization Therapy Follow-up: Role of Remote Monitoring. (2015) (7)
Erratum: The limit of plausibility for predictors of response: Application to biventricular pacing. (JACC: Cardiovascular Imaging (2012) 5 (1046-1065)) (2012) (7)
Biventricular pacing in patients with severe heart failure: has the time come? (2000) (7)
Implantable cardioverter-defibrillator treatment and resynchronisation in heart failure (2004) (6)
Adherence to ESC cardiac resynchronization therapy guidelines: findings from the ESC CRT Survey II. (2020) (6)
Metabolomic Profile in Patients with Heart Failure With Preserved Ejection Fraction Versus Patients With Heart Failure With Reduced Ejection Fraction. (2020) (6)
Paroxysmal Regular Supraventricular Tachycardia: The Diagnostic Accuracy of the Transesophageal Ventriculo‐Atrial Interval (2011) (6)
Trajectories in New York Heart Association functional class in heart failure across the ejection fraction spectrum: data from the Swedish Heart Failure Registry (2022) (6)
Effects of Spinal Cord Stimulation on Cardiac Sympathetic Nerve Activity in Patients with Heart Failure (2017) (6)
Patient profile and outcomes associated with follow‐up in specialty vs. primary care in heart failure (2022) (6)
The Impact of the PR Interval in Patients Receiving Cardiac Resynchronization Therapy: Results From the REVERSE Study. (2017) (6)
The European Heart Journal: leading the fight to reduce the global burden of cardiovascular disease. (2020) (6)
Pacing‐Induced Electrophysiological Remodeling in Hypertrophic Obstructive Cardiomyopathy—Observations on Cardiac Memory (2005) (6)
[Guidelines in cardiac pacing and resynchronization therapy]. (2007) (5)
Dual chamber pacing in patients with hypertrophic obstructive cardiomyopathy with and without obstruction at rest (1996) (5)
Increase in paced heart rate reduces muscle sympathetic nerve activity in heart failure patients treated with cardiac resynchronization therapy. (2015) (5)
Changes in natriuretic peptides after acute hospital presentation for heart failure with preserved ejection fraction: A feasible surrogate trial endpoint? A report from the prospective Karen study. (2017) (5)
Cardiac contractility modulation therapy improves health status in patients with heart failure with preserved ejection fraction: a pilot study (CCM‐HFpEF) (2022) (5)
Pace and ablate better than drugs in patients with heart failure and atrial fibrillation: lessons from the APAF-CRT mortality trial. (2021) (5)
The prognostic significance of atrial fibrillation in heart failure with preserved ejection function: insights from KaRen, a prospective and multicenter study (2017) (5)
Predictors of long‐term outcome in heart failure with preserved ejection fraction: a follow‐up from the KaRen study (2021) (5)
FOCUS ISSUE: CARDIAC RESYNCHRONIZATION THERAPY STATE-OF-THE-ART PAPERS Cardiac Resynchronization Therapy (2005) (5)
COST-EFFECTIVENESS ANALYSIS OF CARDIAC RESYNCHRONIZATION THERAPY IN PATIENTS WITH NYHA I AND NYHA II HEART FAILURE IN SPAIN (2013) (5)
Left atrial far-field sensing by left ventricular leads: a potential hazard in cardiac resynchronisation therapy. (2005) (5)
Spinal cord stimulation in heart failure: effect on disease‐associated biomarkers (2017) (5)
Pacing for repeated vagal reflex-mediated syncope: an old problem with a solution. (2020) (5)
Cardiac resynchronization therapy: results, challenges and perspectives for the future (2016) (5)
Do Patients With Acute Heart Failure and Preserved Ejection Fraction Have Heart Failure at Follow-Up: Implications of the Framingham Criteria. (2020) (4)
When cardiac resynchronization therapy may be harmful: time to wake up. (2015) (4)
Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. (2021) (4)
Importance of systematic right ventricular assessment in cardiac resynchronization therapy candidates: a machine-learning approach. (2021) (4)
Development of a health economic model to evaluate the potential benefits of optimal serum potassium management in patients with heart failure (2018) (4)
Estimating changes in cardiac output using an implanted hemodynamic monitor in heart failure patients* (2010) (4)
Guía ESC 2019 sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes (EASD) (2020) (4)
Pacing in Dilated Cardiomyopathy (1995) (4)
Haemodynamic effects of different basic heart rates in ambulatory heart failure patients treated with cardiac resynchronization therapy. (2013) (4)
Left atrial strain is a predictor of left ventricular systolic and diastolic reverse remodelling in CRT candidates. (2021) (4)
Abstract 3518: Impact of QRS Duration on Clinical Response With Cardiac Resynchronization Therapy: Results From the REVERSE Trial (2009) (4)
P-143 The registry of the European working group on cardiac pacing: 2000 – 2001 (2003) (3)
Cardiac resynchronization therapy with or without defibrillator in patients with heart failure (2021) (3)
Reorganization of heart failure management and improved outcome – the 4D HF Project (2020) (3)
RELATIONSHIP OF QRS MORPHOLOGY ON REVERSE REMODELING AND CLINICAL OUTCOMES WITH CARDIAC RESYNCHRONIZATION THERAPY (CRT) IN MILD HEART FAILURE: RESULTS FROM THE RESYNCHRONIZATION REVERSES REMODELING IN SYSTOLIC LEFT VENTRICULAR DYSFUNCTION (REVERSE) TRIAL (2010) (3)
Do we differ in terms of indications and demographics in cardiac resynchronisation recipients in Poland? Insights from the European CRT Survey II Registry. (2018) (3)
Predictors of primary prevention implantable cardioverter‐defibrillator use in heart failure with reduced ejection fraction: impact of the predicted risk of sudden cardiac death and all‐cause mortality (2022) (3)
Future directions in cardiac resynchronization therapy (2008) (3)
The year in cardiology 2017: arrhythmias and cardiac devices. (2018) (3)
Comparison of current German and European practice in cardiac resynchronization therapy: lessons from the ESC/EHRA/HFA CRT Survey II (2019) (3)
Optimized Implementation of cardiac resynchronization therapy – a call for action for referral and optimization of care (2021) (3)
Ambulatory blood pressure monitoring and blood pressure control in patients with coronary artery disease—A randomized controlled trial (2020) (3)
Cardiac Resynchronization Therapy Follow-up: Role of Remote Monitoring. (2017) (2)
Spanish results of the Second European Cardiac Resynchronization Therapy Survey (CRT-Survey II). (2019) (2)
Identifying risk of adverse outcomes in COVID-19 patients via artificial intelligence–powered analysis of 12-lead intake electrocardiogram (2021) (2)
Outcome and Presentation of Heart Failure in Breast Cancer Patients; Findings from a Swedish register-based study. (2019) (2)
Highlights of the 2007 scientific sessions of the European Society of Cardiology Vienna, Austria, September 1-5, 2007. (2007) (2)
Current clinical practice of cardiac resynchronization therapy in Turkey: Reflections from Cardiac Resynchronization Therapy Survey-II (2020) (2)
P-144 Cardiac pacing in Europe: Indications and demographic data: Years 2000 – 2001 (2003) (2)
How do patients with previous RV pacing respond to upgrading to CRT? Important messages for pacemaker and ICD follow‐up (2014) (2)
Electrical management of heart failure: from pathophysiology to treatment (2022) (2)
Cardiomyopathy and Left Bundle Branch Block: A Farewell to Drugs? (2018) (2)
217Metabolomic profile of patients with new onset heart failure; more microvascular dysfunction in patients with preserved ejection fraction compared to reduced ejection fraction - the PREFERS Study (2019) (1)
Cardiac resynchronization in Poland – comparable procedural routines? Insights from CRT Survey II (2019) (1)
EUROPEAN CARDIAC RESYNCHRONIZATION THERAPY SURVEY II: COMPARISON OF RESULTS IN GEORGIA WITH OTHER COUNTRIES. (2019) (1)
IMPLANTABLE CARDIOVERTER- DEFIBRILLATOR TREATMENT AND (2004) (1)
EFFECT OF SPINAL CORD STIMULATION ON CARDIAC SYMPATHETIC NERVE ACTIVITY IN PATIENTS WITH HEART FAILURE (2016) (1)
Abstract 4346: CRT In Mild Heart Failure: Left Ventricular Remodeling In Relation To Heart Failure Etiology. Results From The Resynchronization Reverses Remodeling In Systolic Left Ventricular Dysfunctie (reverse) Study (2008) (1)
Cardiac resynchronization therapy in Romania – results from the European Society of Cardiology CRT Survey II (2020) (1)
Baseline characteristics of 547 new onset heart failure patients in the PREFERS heart failure study (2022) (1)
Continuous hemodynamic monitoring during diuretic withdrawal in four patients with severe congestive heart failure (2001) (1)
What is the level of evidence for combined cardiac resynchronization and defibrillation therapy in heart failure? reply (2008) (1)
Opportunities for optimization of biventricular pacing using an implanted hemodynamic monitor (2005) (1)
Relationship between iron deficiency and expression of genes involved in iron metabolism in human myocardium and skeletal muscle. (2023) (1)
Cardiac Resynchronisation Therapy (CRT) Survey II: CRT implantation in Europe and in Switzerland. (2018) (1)
Celebrating 50 years of electrical therapies for the heart (2007) (1)
Contemporary practice of CRT implantation in scandinavia compared to Europe (2019) (1)
Integrated care for atrial fibrillation: time for widespread use. (2020) (1)
834 Cardiac pacing in Europe: indications & demographic data: years 2000 – 2001 – 2002 (2005) (1)
Prognostic utility of the assessment of diastolic function in patients undergoing cardiac resynchronization therapy. (2021) (1)
Methods Employed to Assess Left Ventricular Ejection Fraction in Patients Referred for Cardiac Resynchronization Therapy in Poland as Compared to other European Countries. Results from the European Cardiac Resynchronization Therapy Survey II. (2019) (1)
Upgrades from Previous Cardiac Implantable Electronic Devices Compared to De Novo Cardiac Resynchronization Therapy Implantations: Results from CRT Survey-II in the Turkish Population (2022) (1)
Combipolar Sensing in Dual Chamber Pacing: Is There Still a Need for Bipolar Leads in the Atrium? (2001) (1)
Second European Society of Cardiology Cardiac Resynchronization Therapy Survey: the Italian cohort. (2020) (1)
Abstract 13471: Implantable Defibrillators Improve Survival in Mildly Symptomatic Heart Failure Patients Receiving Cardiac Resynchronization Therapy: Analysis of the 5-Year Follow-Up of REVERSE (2012) (1)
Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial (2021) (1)
Rapid Atrial Pacing Does Not Decrease the Atrial Defibrillation Threshold (2003) (1)
Croatian National Data and Comparison with European Practice: Data from the Cardiac Resynchronization Therapy Survey II Multicenter Registry (2018) (1)
HFpEF and HFrEF display different anabolic phenotypes as assessed by IGF-1 and IGFBP-1 (2016) (1)
Improvement of blood pressure control and physicians’ management over time in patients with coronary artery disease (2016) (1)
[Biventricular pacing as a new therapeutic method in heart failure. An alternative for patients with intraventricular conduction disorders]. (2000) (1)
Highlights of the 2006 scientific sessions of the European Society of Cardiology: Barcelona, Spain, September 2-5, 2006. (2006) (1)
Second European Society of Cardiology Cardiac Resynchronization Therapy Survey: the Italian cohort. (2020) (1)
Age is an independent predictor of right ventricular geometry and function in males only. (2012) (0)
Cardiac resynchronization therapy in the Czech Republic - Data from the EHRA CRT Survey II multicenter registry (2018) (0)
The European Heart Journal: fulfilling the mission. (2022) (0)
The Membership Committee of the ESC. (2019) (0)
Cardiac Resynchronisation Therapy in Patients with NYHA Class I–II (2006) (0)
083 Heart failure with preserved ejection fraction (2011) (0)
Abstract 17300: Changes in Natriuretic Peptides After Hospitalization for Heart Failure With Preserved Ejection Fraction: A Feasible Surrogate Endpoint? A Report From the Prospective Karen Study (2016) (0)
RELATIONSHIP BETWEEN HYPERKALAEMIA AND DOWN-TITRATION OR DISCONTINUATION OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS IN UK PATIENTS WITH CKD (2018) (0)
Abstract 18532: New Prognostic Factors in Heart Failure With Preserved Ejection Fraction: The KaRen Study (2013) (0)
56-70: CRT Survey II (2016) (0)
The Association of Left Ventricular Remodeling with CRT Outcomes. (2022) (0)
Chronic right heart pressure measurements with the chronicle™ implantable hemodynamic monitor: 12-week follow-up in a multicenter trial in chronic heart failure patients (1999) (0)
LEFT VENTRICULAR REVERSE REMODELING PREDICTS MORTALITY: RESULTS FROM THE REVERSE STUDY (2011) (0)
CRT Survey II: a European Society of Cardiology (ESC) survey of cardiac resynchronization therapy—an Irish subset analysis (2020) (0)
Cardiac resynchronization revisited: what is the next step? (2015) (0)
Cardiac Resynchronization Therapy Improves Outcomes in Patients With Intraventricular Conduction Delay But Not Right Bundle Branch Block: A Patient-Level Meta-Analysis of Randomized Controlled Trials (2023) (0)
P-367 Europe anno 2001: New and old technology (2003) (0)
[Pacemaker in hypertrophic obstructive cardiomyopathy. A new efficient treatment of heart disease]. (1996) (0)
832 The registry of the European Heart Rhythm Association: Years 2000 – 2001 – 2002 (2005) (0)
AV-delay optimization in cardiac resynchronization therapy using an implanted hemodynamic monitor (2005) (0)
Outcomes of Conduction System Pacing for Cardiac Resynchronization Therapy in Patients with Heart Failure: A Multicenter Experience. (2023) (0)
625 Estimation of cardiac output from right ventricular pressures using an implanted hemodynamic monitor (2005) (0)
Abstract 1898: CRT In Patients With Asymptomatic And Mildly Symptomatic Heart Failure: Baseline Characteristics Of The Resynchronization Reverses Remodeling In Systolic Left Ventricular Dysfunction (reverse) Study Population. (2007) (0)
Biventricular pacing reduces hospital days in patients with severe congestive heart failure (2001) (0)
Upgrades from Previous Cardiac Implantable Electronic Devices Compared to De Novo Cardiac Resynchronization Therapy Implantations: Results from CRT Survey-II in the Turkish Population. (2022) (0)
Cardiac contractility modulation therapy promising for patients with HFpEF (2022) (0)
Remodeling in Systolic Left Ventricular Dysfunction ( REVERSE ) Study Outcomes in Mild Heart Failure : Results From the Resynchronization Reverses Effect of QRS Duration and Morphology on Cardiac Resynchronization Therapy (2012) (0)
P2790Novel endomyocardial micro-biopsy device for higher precision and reduced complication risks (2019) (0)
Abstract 2954: Monitoring of Breathing Patterns in Heart Failure Patients Using Pressure-Derived Respiration (2006) (0)
2177Cardiac resynchronization therapy in patients greater than 75 years of age - results from the European Society of Cardiology Survey II with 11 088 patients (2019) (0)
Myocardial hibernation : adaptation to ischaemia The concept of hibernation (2005) (0)
Quality of life with implanted devices (2020) (0)
European Heart Rhythm Society, EHRA EUROPACE-CARDIOSTIM2015: Society Introduction (2015) (0)
Correction to: CRT Survey II: a European Society of Cardiology (ESC) survey of cardiac resynchronization therapy—an Irish subset analysis (2020) (0)
REVERSE REMODELING WITH CARDIAC RESYNCHRONIZATION THERAPY PREDICTS LONG-TERM SURVIVAL IN MILDLY SYMPTOMATIC HEART FAILURE (2013) (0)
The year in cardiology 2017 : prevention (2018) (0)
National healthcare expenditure influences CRT implantations- results from CRT Survey II with 11088 patients (2020) (0)
Cardiac resynchronisation therapy in heart failure patients with ischaemic vs non-ischaemic aetiology : results from 11088 patients in the ESC CRT Survey II (2018) (0)
561 Targeting septal work and viability identifies responders to cardiac resynchronization therapy (2020) (0)
446 A Pilot Study of Screening CRT/ICD Patients for Heart Transplantation and Left Ventricular Assist Device Referral (2012) (0)
Abstract 16836: Continued Remodeling Despite Cardiac Resynchronization Therapy in Mildly Symptomatic Heart Failure Identifies Subjects at Increased Mortality: Long Term Follow-Up Results From REVERSE (2014) (0)
Biventricular Stimulation: A BLOCKbuster in Cardiac Pacing? (2016) (0)
The European Society of Cardiology Cardiac Resynchronization Therapy Survey II: A comparison of cardiac resynchronization therapy implantation practice in Europe and France. (2019) (0)
Characteristics of ambulatory daytime, nighttime and resting right ventricular pressures in chronic heart failure patients with implantable hemodynamic monitors (1999) (0)
537CRT in women- results from the ESC CRT Survey II with 11 088 patients (2018) (0)
EDITORIAL Cardiac resynchronization therapy (2008) (0)
0370: The prognostic significance of atrial fibrillation in heart failure with preserved ejection function: insights from KaRen, a prospective and multicenter study (2016) (0)
Godina 2017. u kardiologiji: aritmije i srčani uređaji (2018) (0)
LEFT BUNDLE BRANCH AREA PACING FOR CARDIAC RESYNCHRONIZATION THERAPY: A MULTICENTER PROSPECTIVE STUDY (2022) (0)
Rationale and design of CONTINUITY: a Phase 4 randomized controlled trial of continued post-discharge sodium zirconium cyclosilicate treatment versus standard of care for hyperkalemia in chronic kidney disease (2023) (0)
Rationale : preserved and reduced ejection fraction epidemiological regional study in stockholm (PREFERS) (2015) (0)
Impaired systolic function in heart failure with preserved ejection fraction: A specific phenotype? (2019) (0)
Extracellular vesicles in heart failure – A study in patients with heart failure with preserved ejection fraction or heart failure with reduced ejection fraction characteristics undergoing elective coronary artery bypass grafting (2022) (0)
Associations Between Plasma Natriuretic Peptide Levels, Symptoms, and Left Ventricular Function in Patients With Chronic Aortic Regurgitation (2003) (0)
Abstract 4852: Changes In Left Ventricular Structure And Function Over 12 Months In Patients With Mild Or Asymptomatic Heart Failure With Previous Symptoms In The Resynchronization Reverses Remodelling In Systolic Left Ventricular Dysfunction (reverse) Study (2008) (0)
Spatial detection of fetal marker genes expressed at low level in adult human heart tissue (2017) (0)
IRON DEFICIENCY IN HEART FAILURE: SCREENING, PREVALENCE, INCIDENCE, IRON NEED, AND OUTCOMES (2023) (0)
296 Monitoring of patients activity in chronic heart failure by pacemaker devices: a novel marker for individual improvement after CR? (2003) (0)
Response by Schrage et al to Letter Regarding Article, "Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedish Heart Failure Registry". (2020) (0)
European CRT Survey II – Bulgarian data (2018) (0)
Circulating neuregulin1-beta in heart failure with preserved and reduced left ventricular ejection fraction (2020) (0)
Benchmarking Belgian CRT practice against the rest of Europe: insights from the ESC-CRT survey II (2020) (0)
Cardiac resynchronization therapy improves left ventricular volumes in patients with ejection fraction between 36 and 50% with left bundle branch block: MIRACLE EF study (2015) (0)
085: Heart failure with preserved ejection fraction: changes in clinical parameters between acute presentation and subsequent follow-up (2013) (0)
Trial ( Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction : Insights From the European Cohort of the REVERSE Patients With Asymptomatic or Mildly Symptomatic Left Ventricular Prevention of Disease Progression by Cardiac Resynchronization Therapy in (2009) (0)
0548: Heart failure with preserved ejection fraction: an echocardiographic based approach to assess the prognosis. A report from the large prospective KaRen study (2015) (0)
093 - Associations between clinical characteristics and NT-proBNP in heart failure with preserved ejection fraction: data from the KaRen study (2013) (0)
Efficacy of cardiac resynchronization therapy in atrial fibrillation (2007) (0)
Association Of Comorbidities With Clinical Outcomes Of Cardiac Resynchronization Therapy: A Meta-analysis Of Patient-level Data From Eight Major Clinical Trials (2023) (0)
A03-1 Long-term clinical outcome and device performance of biventricular pacing: A single center evaluation from three-year follow-up of consecutive heart failure patients (2003) (0)
What determines who gets Cardiac Resynchronization Therapy in Europe? A comparison between ESC-HF-LT registry, SwedeHF registry and ESC-CRT Survey II. (2023) (0)
099 Heart failure with preserved ejection fraction - characteristics and prognosis - first results from the prospective KaRen study (2012) (0)
Transcriptomics of cardiac biopsies reveals differences in patients with or without diagnostic parameters for heart failure with preserved ejection fraction (2019) (0)
Cardiac resynchronization in heart failure: Recent advances and their practical implications. (2023) (0)
Screening Patients with Cardiac Resynchronization Therapy/Implantable Cardioverter-Defibrillator for Indications for Heart Transplantation and Left Ventricular Assist Device : A Pilot Study (2013) (0)
Abstract 11601: Reduced 30-Day Hospital Readmissions in Systolic Heart Failure Patients With Cardiac Resynchronization Therapy: Evidence From 5 Randomized Controlled Trials (2014) (0)
Corrigendum to "Changes in natriuretic peptides after acute hospital presentation for heart failure with preserved ejection fraction: A feasible surrogate trial endpoint? A report from the prospective Karen study" [Int. J. Cardiol. 226 (2017) 65-70]. (2018) (0)
066: Atrial arrhythmias in patients with heart failure and preserved ejection fraction. Results from the prospective French and Swedish KaRen study (2013) (0)
Heart failure with preserved ejection fraction: echocardiographic characteristics in relation to right ventricular function (2013) (0)
Iron deficiency in heart failure: screening, prevalence, incidence and outcome Data from the Swedish Heart Failure registry and the Stockholm CREAtinine Measurements collaborative project. (2023) (0)
Myocardial micro-biopsy procedure for molecular characterization with increased precision and reduced trauma (2020) (0)
EFFECT OF DIABETES MELLITUS ON THE REVERSE REMODELING RESPONSE AND CLINICAL OUTCOMES WITH CARDIAC RESYNCHRONIZATION THERAPY IN MILDLY SYMPTOMATIC AND ASYMPTOMATIC HEART FAILURE PATIENTS: A SUB-STUDY OF THE REVERSE TRIAL (2012) (0)
Myeloperoxidase and urate in patients with heart failure and preserved ejection fraction (2016) (0)
MO151: A Randomized Controlled Trial of Sodium Zirconium Cyclosilicate Versus Standard of Care for Hyperkalaemia in Chronic Kidney Disease: Phase 4 Continuity Study Design and Rationale (2022) (0)
PREDICTORS OF NON-USE OF IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS FOR PRIMARY PREVENTION OF SUDDEN CARDIAC DEATH IN HEART FAILURE (2020) (0)
P5282Differentiated health outcomes and potential protein markers based on unsupervised analysis of heart failure patients with preserved ejection fraction in the KaRen study (2017) (0)
P764A quality improvement program for heart failure involving structured patient data, diagnosis and organization of care - results from the 4D heart failure project (2019) (0)
Second European Cardiac Resynchronisation Therapy Survey (Crt Survey Ii): Latvian Data Compared to Europe (2020) (0)
073_16826-M1 Do Patients With Acute Heart Failure and Preserved Ejection Fraction Have Heart Failure at Follow-Up - Impact of Framingham Criteria (2017) (0)
Cardiac Resynchronisation Therapy in Patients with Atrial Fibrillation: Are Results as Good as in Patients with Sinus Rhythm? (2004) (0)
B-PO01-094 ARTIFICIAL INTELLIGENCE (AI) CAN IDENTIFY RISK OF DEATH IN COVID-19 PATIENTS USING 12-LEAD INTAKE ELECTROCARDIOGRAM (ECG) ALONE (2021) (0)
CP17: OPTIMIZATION OF THE AV DELAY IN CARDIAC RESYNCHRONIZATION THERAPY USING AN IMPLANTED HEMODYNAMIC MONITOR (2005) (0)
Septal scar predicts non-response to cardiac resynchronization therapy (2021) (0)
Cardioverter-DefibrillatorRegistry.Asurveyofthenationalactivityduringtheyears (2015) (0)
FP371RECURRENT HYPERKALAEMIA AND ASSOCIATION WITH LENGTH-OF-STAY AND MORTALITY FOLLOWING HOSPITALISATION: REAL-WORLD EVIDENCE FROM UK PATIENTS WITH CKD (2018) (0)
How may dilated cardiomyopathy benefit from cardiac pacing (1996) (0)
Long-term outcomes in heart failure with preserved ejection fraction: Predictors of cardiac and non-cardiac mortality. (2023) (0)
18.5 Biventricular pacing increases myocardial oxygen consumption during stress: a study using 1- 11C-acetate (ACE) positron emission tomography (2001) (0)
CRT IN MILD HEART FAILURE: RESPONSE IN RELATION TO HEART FAILURE ETIOLOGY? 24 MONTH RESULTS FROM THE RESYNCHRONISATION REVERSES REMODELLING IN SYSTOLIC LEFT VENTRICULAR DYSFUNCTION (REVERSE) STUDY (2010) (0)
CRT-P or CRT-D in heart failure patients: the RESET-CRT project-a prelude to the randomized controlled RESET-CRT study. (2022) (0)
PMD27 Cost-Effectiveness Analysis of Cardiac Resynchronization Therapy in Patients with Asymptomatic to Mild Heart Failure Based on the European Cohort of the reverse Study from the Spanish Health System Perspective (2011) (0)
New Year's resolutions for 2008. European cardiologists share their goals and aspirations, professional, in practice, and personal, for 2008. Interviews by Lindy van den Berghe. (2008) (0)
INFLUENCE OF LEFT AND RIGHT VENTRICULAR LEAD-TIP POSITION ON THE RESPONSE TO CARDIAC RESYNCHRONIZATION THERAPY: RESULTS FROM THE REVERSE STUDY (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Cecilia Linde?

Cecilia Linde is affiliated with the following schools:

Uppsala University
Ohio State University
Karolinska Institute

Cecilia Linde's Academic­Influence.com Rankings

Why Is Cecilia Linde Influential?

Cecilia Linde's Published Works

Published Works

What Schools Are Affiliated With Cecilia Linde?

Cecilia Linde's AcademicInfluence.com Rankings